Background Nowadays, researchers are leveraging the mRNA-based vaccine technology
used to develop personalized immunotherapy for cancer. However, its application against …

Background As an important part of tumor immunotherapy for adjunct, therapeutic tumor
vaccines have been effective against multiple solid cancers, while their efficacy against …

Background Although mRNA vaccines have been efficient for combating a variety of tumors,
their effectiveness against glioma remains unclear. There is growing evidence that …

Purpose Glioblastoma (GBM) is the most common primary brain tumor in adults and is
notorious for its lethality. Given its limited therapeutic measures and high heterogeneity, the …

Background: Clinical benefits from standard therapies against glioblastoma (GBM) are
limited in part due to the intrinsic radio-and chemo-resistance. As an essential part of tumor …

The use of vaccines for cancer therapy is a promising immunotherapeutic strategy that has
been shown to be effective against various cancers. Vaccines directly target tumors but their …

Rationale: Diffuse glioma patients have high mortality and recurrence despite multimodal
therapies. This study aims to identify the potential tumor antigens for mRNA vaccines and …

Glioma is the most common primary brain tumor, characterized by a consistently high patient
mortality rate and a dismal prognosis affecting both survival and quality of life. Substantial …

Cancer stem cells are initiating cells of cancer and propagate its growth through self-
renewal and differentiation of its daughter cells. CD133 is a cell surface antigen that is …

Glioblastoma (GBM), also known as grade IV astrocytoma, is the most common and deadly
type of central nervous system malignancy in adults. Despite significant breakthroughs in …